The estimated Net Worth of Timothy J Schroeder is at least $2.2 Million dollars as of 12 July 2023. Timothy Schroeder owns over 10,000 units of INmune Bio stock worth over $512,025 and over the last 5 years Timothy sold INMB stock worth over $1,686,282.
Sign up
Timothy Schroeder INMB stock SEC Form 4 insiders trading
Timothy has made over 6 trades of the INmune Bio stock since 2021, according to the Form 4 filled with the SEC. Most recently Timothy sold 10,000 units of INMB stock worth $110,100 on 12 July 2023.
The largest trade Timothy's ever made was selling 30,000 units of INmune Bio stock on 9 July 2021 worth over $696,300. On average, Timothy trades about 7,040 units every 69 days since 2019. As of 12 July 2023 Timothy still owns at least 82,187 units of INmune Bio stock.
You can see the complete history of Timothy Schroeder stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Timothy Schroeder's mailing address?
Timothy's mailing address filed with the SEC is C/O INMUNE BIO INC,, 225 NE MIZNER BLVD., SUITE 640, BOCA RATON,, FL, 33432.
Insiders trading at INmune Bio
Over the last 5 years, insiders at INmune Bio have traded over $5,236,202 worth of INmune Bio stock and bought 82,618 units worth $534,813 . The most active insiders traders include Linda F Powers, Edgardo Jr Baracchini, and Inc Xencor. On average, INmune Bio executives and independent directors trade stock every 51 days with the average trade being worth of $117,087. The most recent stock trade was executed by Scott Juda on 25 June 2024, trading 5,000 units of INMB stock currently worth $36,350.
What does INmune Bio do?
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
What does INmune Bio's logo look like?
Complete history of Timothy Schroeder stock trades at INmune Bio
INmune Bio executives and stock owners
INmune Bio executives and other stock owners filed with the SEC include:
-
Dr. Raymond Joseph Tesi M.D.,
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman -
David J. Moss M.B.A.,
CFO, Treasurer & Sec. -
Dr. Raymond Joseph Tesi,
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman -
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.,
Chief Scientific Officer & Chief Manufacturing Officer -
Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR,
Chief Scientific Officer & Chief Manufacturing Officer -
Dr. Christopher J. Barnum,
Director of Neuroscience -
Joshua S. Schoonover Esq.,
Assoc. Gen. Counsel -
Scott Juda,
Director -
Inc Xencor,
-
Timothy J Schroeder,
Director -
Edgardo Jr Baracchini,
Director -
James Kelly Ganjei,
Director -
Linda F Powers,
-
Marcia Allen,
Director -
Raymond Joseph Tesi,
President and CEO -
Mark William Lowdell,
Chief Scientific Officer -
David J Moss,
Chief Financial Officer